Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
Last trade$24.02
Day change-$0.055 (-0.23%)
Day range$23.42 – $24.36
Volume132,896
Market cap$673M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$672.77M
Price / earnings
—
Price / book
0.68×
Price / sales
2.04×
EV / sales
1.78×
EV / EBITDA
-5.82×
Profitability
Earnings per share
-$3.25
Return on assets
-8.43%
Return on equity
-9.18%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.34×
Quick ratio
5.34×
Cash ratio
1.21×
Cash flow
Price / cash flow
46.63×
Price / free cash flow
—
Free cash flow
-$1.4M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FLGT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$90.41M
$85.39M
$71.14M
$83.34M
$84.07M
$81.8M
$73.46M
$76.21M
Cost of revenue
$58.47M
$59.71M
$49.65M
$50.75M
$48.56M
$47.37M
$45.12M
$44.37M
Gross profit
$31.95M
$25.68M
$21.49M
$32.58M
$35.51M
$34.44M
$28.35M
$31.85M
Selling, general and administrative
$38.37M
$42.42M
$39.91M
$52.62M
$34.98M
$38.68M
$33.76M
$33.88M
Research and development
$13.64M
$14.55M
$14.18M
$14.17M
$13.86M
$13.48M
$12.4M
$12.11M
Total operating expenses
$54.49M
$61.75M
$56.11M
$68.82M
$50.86M
$64.07M
$48.14M
$47.98M
Operating income
-$22.55M
-$36.07M
-$34.62M
-$36.24M
-$15.35M
-$29.64M
-$19.8M
-$16.14M
Interest expense
-$7K
-$59K
-$17K
-$16K
-$28K
-$17K
-$14K
-$40K
Income before taxes
-$14.04M
-$29.69M
-$25.98M
-$29.27M
-$7.51M
-$21.52M
-$11.72M
-$8.05M
Income taxes
-$704K
$29K
-$704K
-$5.62M
-$683K
-$2.26M
$176K
-$1.86M
Net income
-$13.34M
-$29.72M
-$25.27M
-$23.65M
-$6.83M
-$19.26M
-$11.9M
-$6.19M
Net income attributable to common shareholders
-$13.15M
-$29.53M
-$24.83M
-$23.42M
-$6.61M
-$18.96M
-$11.53M
-$5.89M
EBITDA
-$15.73M
-$26.23M
-$28.62M
-$30.13M
-$9.31M
-$13.66M
-$13.88M
-$9.94M
Basic earnings per share
-$0.48
-$1.05
-$0.80
-$0.76
-$0.21
-$0.62
-$0.37
-$0.19
Diluted earnings per share
-$0.48
-$1.05
-$0.80
-$0.76
-$0.21
-$0.62
-$0.37
-$0.19
Recent news
Company coverage with links to the original publishers.
Fulgent Genetics reported a Q3 loss of $0.09 per share, significantly beating the consensus estimate of a $0.65 loss, representing an 86.15% earnings surprise. Revenue reached $90.41 million, surpassing estimates by 4.77%. However, the stock has underperformed the market by 25.1% year-to-date. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.
Law firm Lowey Dannenberg is investigating Fulgent Genetics Inc. for potential violations of federal securities laws following the company's February 27, 2026 earnings report, which showed full year 2025 revenue of $322.7 million falling slightly short of updated guidance and sequential fourth quarter revenue decline. The firm is encouraging investors who suffered losses to contact them.
Kirby McInerney LLP is investigating Fulgent Genetics Inc. for potential securities law violations following a significant stock price decline. On February 27, 2026, Fulgent reported lower-than-expected 2026 guidance due to its largest customer moving work in-house, causing shares to drop 38.1% from $24.76 to $15.33. The law firm is seeking investors who purchased Fulgent securities to participate in the ongoing investigation.
The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.